The BACKBEAT trial targets 284 evaluable randomized patients by end-Q3 2026, with primary endpoint data targeted for a Q2 2027 late-breaker.
Virtue pivotal trial enrollment continues.
Q2 FY26 results and cash position
Orchestra BioMed posted Q2 net loss attributable to common stockholders of $24.1 million, widening 23% year over year; loss per share improved to $0.38 from $0.50.
Revenue fell to $88,000 from $836,000 a year earlier, with partnership revenue at no revenue versus $667,000.
R&D expense rose 20% to $16.6 million on higher clinical trial activity; SG&A declined 7% to $5.8 million.
Cash, cash equivalents and marketable securities totaled ; net cash used in operating activities and fixed assets was .
OBIO•
